The Prevention and Remediation of Insulin Multimorbidity in Europe (PRIME) project, which kicked off in January this year, has recently launched its website. The goal of the 4-year PRIME project is to understand the insulin-related mechanisms that underly metabolic disorders such as type 2 diabetes, as well as brain disorders such as Alzheimer’s disease and obsessive-compusive disorder. PRIME brings together a multidisciplinary team that includes academic institutions in Italy, Spain and Germany as well as SMEs, NGOs and patient organisations, and is led by Prof. Barbara Franke from Radboud University Medical Center in Nijmegen, the Netherlands. Alzheimer Europe is participating in the PRIME Scientific and Ethical Advisory Board and will contribute to the dissemination and communication objectives of the project. The PRIME project website can be found here: https://prime-study.eu/
PRIME receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847879.
